Biodesix (NASDAQ:BDSX) & Aeon Global Health (OTCMKTS:AGHC) Head-To-Head Contrast

Aeon Global Health (OTCMKTS:AGHC) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and price targets for Aeon Global Health and Biodesix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aeon Global Health	0	0	0	0	0.00
Biodesix	0	0	5	0	3.00

Biodesix has a consensus price target of $3.06, indicating a potential upside of 166.09%. Given Biodesix’s stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than Aeon Global Health.

Earnings & Valuation

This table compares Aeon Global Health and Biodesix”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aeon Global Health	N/A	N/A	N/A	N/A	N/A
Biodesix	$65.56 million	2.55	-$52.15 million	($0.39)	-2.95

Aeon Global Health has higher earnings, but lower revenue than Biodesix.

Insider and Institutional Ownership

21.0% of Biodesix shares are held by institutional investors. 11.5% of Aeon Global Health shares are held by company insiders. Comparatively, 69.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Aeon Global Health and Biodesix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aeon Global Health	N/A	N/A	N/A
Biodesix	-66.84%	-275.79%	-43.05%

Summary

Biodesix beats Aeon Global Health on 6 of the 9 factors compared between the two stocks.

About Aeon Global Health

AEON Global Health Corp. is a growth oriented provider of personalized, actionable medical informatics, and telemedicine. It offers a comprehensive menu of diagnostic and laboratory developed assays, as well as interpretive data for a range of inherited conditions. The company was founded by Hanif A. Roshan and Shawn Desai in August 1985 and is headquartered in Gainesville, GA.

About Biodesix

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.